In conclusion, for patients with advanced metastatic melanoma in the AMBER study, cobolimab plus dostarlimab had a manageable safety profile and demonstrated preliminary antitumor activity, particularly in patients naïve to anti–PD-(L)1 and CTLA-4 therapy. This evidence concerns the gene CTLA4 and metastatic melanoma.